Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

10.59 -1.69 (-13.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Why Volcon Shares Are Trading Lower By 19%; Here Are 20 Stocks Moving Premarket
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 38.7% to $0.1421 in pre-market trading after gaining 10% on Thursday. 
Via Benzinga
Mitek Systems, Arm Holdings And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mostly higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Why Shares of Iovance Biotherapeutics Dropped Thursday
The biotech stock's lead therapy is looking at some competition. 
Via The Motley Fool
Where Iovance Biotherapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Iovance Biotherapeutics
Via Benzinga
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi. 
Via Benzinga
Iovance Biotherapeutics Stock Is Down 15%: What's Going On?
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading lower by 15.8% to $4.58, despite a lack of company-specific news for the session. 
Via Benzinga
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Cathie Wood Continues Iridium Shopping Spree — Ark Invest Buys $3.6M Worth Of Satellite Company's Stock
Via Benzinga
Cathie Wood Buys $3.4M Worth Of Shares In This Payments Software Firm — Also Increases Exposure To Iridium Stock
Via Benzinga
Cathie Wood's Ark Invest Sells Robinhood, Coinbase Shares — Buys $3.5M Worth Of Stock Of This Social Media Company
Via Benzinga
7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. 
Via InvestorPlace
Cathie Wood's Ark Invest Continues To Sell Shares Of Warren Buffett-Backed BYD — Coinbase Holdings Trimmed As Well
Via Benzinga
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
Oral Presentation of Cohort 3A Data from IOV-COM-202 Phase 2 Clinical Trial of LN-145 in Combination with Pembrolizumab in Anti-PD1-naïve Advanced (metastatic or unresectable) Non-Small Cell Lung... 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Why Iovance Biotherapeutics Stock Is Dropping Tuesday
The company is doing a $150 million public stock offering. 
Via The Motley Fool
DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership
Ginkgo Bioworks (DNA) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk. 
Via InvestorPlace
Why Is Zillow (Z) Stock Up 8% Today?
Zillow (Z) stock is on the rise Tuesday after the tech real-estate marketplace company's shares got an upgrade from Piper Sandler. 
Via InvestorPlace
Why Is Iovance Biotherapeutics (IOVA) Stock Down 10% Today?
Iovance Biotherapeutics (IOVA) stock is sliding lower on Tuesday after the company announced details of a public share offering. 
Via InvestorPlace
Why Iovance Biotherapeutics Shares Are Tumbling Tuesday
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading lower Tuesday after the company announced the pricing of a public o 
Via Benzinga
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
Broader markets seemed likely to start out on a positive note despite these two outliers. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.